Company Information
USD
7.27
- (-2%)
NASDAQ:ATRA, ATARA BIOTHERAPEUTICS, INC.
Industry: Biotechnology
End of Day: 9 May 2025 GMT-4
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Address
2380 Conejo Spectrum St
Suite 200
Website
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Mr. Ameet Mallik
Director
Mr. Eric Hyllengren
CFO/Chief Accounting Officer/Senior VP
Ms. Jill Henrich
Other Corporate Officer
Mr. Cokey Nguyen
Chief Scientific Officer
Dr. Carol G. Gallagher,Pharm.D.
Chairman of the Board/Director
Mr. Eric L. Dobmeier
Director
Mr. Matthew K. Fust
Director
Mr. William K. Heiden
Director
Dr. Pascal Touchon, D.V.M.
CEO/Director/President
Mr. Amar Murugan
Chief Legal Officer/Executive VP
Dr. Maria Grazia Roncarolo, M.D.
Director
Ownership
Institution Holdings
EcoR1 Capital, LLC
10,067,043 (9.877%)
BlackRock Inc
7,087,213 (6.954%)
Vanguard Group Inc
6,686,043 (6.560%)
Redmile Group, LLC
6,280,813 (6.162%)
D. E. Shaw & Co LP
3,910,416 (3.837%)
UBS Group AG
3,693,225 (3.624%)
BlackRock Fund Advisors
3,536,127 (3.469%)
AQR Capital Management LLC
2,932,310 (2.877%)
Millennium Management LLC
2,920,980 (2.866%)
State Street Corporation
2,784,200 (2.732%)
Funds Holdings
iShares Russell 2000 ETF
2,398,245 (2.353%)
iShares Russell 2000 Value ETF
845,115 (0.829%)
JPMorgan US Small Company Fund
510,828 (0.501%)
Vanguard Russell 2000 Index Fund
327,375 (0.321%)
SPDR® Russell 2000 US Small Cap ETF
295,668 (0.290%)
Vanguard Health Care Index Fund
275,545 (0.270%)
NT R2000 Index Fund - NL
272,047 (0.267%)
BlackRock - Extended Mkt Fund CF
227,436 (0.223%)
NT R2000 Index Fund - DC - NL
214,240 (0.210%)
BlackRock Extended Equity Market
192,885 (0.189%)
Make Smart Investment Choices